Related Experiment Video
Updated: Jul 9, 2025
Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells
Published on: June 10, 2022
Progress and Challenges of Messenger RNA Vaccines in the Therapeutics of NSCLC
Eftychia Kiousi1, Vasiliki Lyraraki1, Georgia Lamprini Mardiki1
1Oncology Unit, Third Department of Medicine, Sotiria General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Abstract:
The introduction of immune checkpoint inhibitors in the therapeutics of non-small cell lung cancer (NSCLC) has been a game-changer in the management of patients with lung cancer; however, challenges do exist since a non-negligible subset of patients does not respond to therapy. Various immunotherapeutic anticancer strategies have been increasingly developed in recent years, including monoclonal antibodies, adoptive T-cell therapy, and vaccines. Fueled by their rapid drug development and successful implementation during the COVID-19 pandemic, messenger RNA (mRNA) vaccines represent an emerging therapeutic approach in other fields of medicine, including oncology. Several clinical trials are currently being conducted to assess the safety and efficacy of mRNA vaccines regarding a variety of solid tumors. Combining mRNA vaccines with other immunotherapeutic approaches has also been suggested and is currently under investigation. Although, in the case of NSCLC, the investigation is still in its early stages, the initial results raise the need for clinician awareness of these promising therapies. To this end, in the present review, we aim to summarize current advances in the development of mRNA vaccines in NSCLC therapeutics and discuss pragmatic challenges regarding their drug development and the different opportunities for implementation.
Insights
Messenger RNA (mRNA) vaccines show promise for treating non-small cell lung cancer (NSCLC), offering a new avenue beyond current immunotherapies. Further research is needed to overcome challenges and optimize their use in NSCLC treatment.
Area of Science:
- Oncology
- Immunotherapy
- Vaccinology
Background:
- Immune checkpoint inhibitors have transformed non-small cell lung cancer (NSCLC) treatment, but many patients lack response.
- Emerging immunotherapeutic strategies, including vaccines, are being developed to improve patient outcomes.
- Messenger RNA (mRNA) technology, proven effective during the COVID-19 pandemic, is now being explored for cancer therapy.
Purpose of the Study:
- To review the current advancements in mRNA vaccine development for NSCLC.
- To discuss the challenges and opportunities associated with mRNA vaccine implementation in NSCLC therapeutics.
Main Methods:
- Literature review of current clinical trials and research on mRNA vaccines in NSCLC.
- Analysis of drug development pathways and implementation strategies for mRNA-based cancer therapies.
Main Results:
- Several clinical trials are evaluating mRNA vaccines for various solid tumors, including early-stage investigations in NSCLC.
- Combining mRNA vaccines with other immunotherapies is an active area of research.
- Initial findings suggest mRNA vaccines are a promising therapeutic approach for NSCLC.
Conclusions:
- mRNA vaccines represent a novel and emerging therapeutic option for NSCLC.
- Addressing drug development challenges and exploring implementation strategies are crucial for clinical success.
- Clinicians should be aware of the potential of mRNA vaccines in NSCLC treatment.
